Overview of the 340B Drug Pricing Program

Recommendations

Info

Acknowledgments The Commission benefited from the individuals who generously offered their time and knowledge. Our thanks to the following: Gerardine Brennan, James Cosgrove, Beth Feldpush, Erin Hertzog, Krista Pedley, John Rigg, David Tawes, Maureen Testoni, and Laurel Todd. The Commission would also like to thank Hannah Fein, Mary Gawlik, and Melissa Lux for their help editing this report. Overview of the 340B Drug Pricing Program | May 2015 iii
Page 1 and 2: M a y 2 0 1 5 Report to the Congres
Page 6: Executive summary
Page 9 and 10: purchase outpatient drugs at steep
Page 12 and 13: Description of the 340B program The
Page 14 and 15: Several types of providers are elig
Page 16 and 17: Formula for calculating 340B ceilin
Page 18 and 19: Covered entities must ensure that m
Page 20 and 21: Figure FIGURE 2 2 Title here Amount
Page 22 and 23: care hospitals in 2004, growing to
Page 24 and 25: Regarding the third option for elig
Page 26 and 27: (Health Resources and Services Admi
Page 28 and 29: 9 A single-source drug is typically
Page 30 and 31: General 2015). In response, HRSA pl
Page 32 and 33: Health Resources and Services Admin
Page 34: A P P E N D I XA Method for estimat
Page 37 and 38: single-source or innovator multiple
Page 39 and 40: References Office of Inspector Gene
Page 41 and 42: The Commission The Medicare Payment
Page 43 and 44: Commission staff Mark E. Miller, Ph

Overview of the 340B Drug Pricing Program

Create successful ePaper yourself

Delete template?

Save as template?